8-K filing — Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Minerva Neurosciences announced participation in two upcoming investor conferences (Wells Fargo Healthcare Conference on September 8 and Cantor Global Healthcare Conference on September 9, 2026). The company is conducting a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline efficacy data expected in the second half of 2027. The company has also established a Scientific Advisory Board of leading experts in psychiatry and neuroscience.

Minerva Neurosciences shares are trading higher after Jefferies upgraded the stock from Hold to Buy rating and raised the price target from $7.5 to $10.

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.

Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10

Jefferies analyst Biren Amin upgrades Minerva Neurosciences (NASDAQ:NERV) from Hold to Buy and raises the price target from $7.5 to $10.